• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半剂量和三分之二剂量光动力疗法治疗厚脉络膜新生血管病变后息肉样病变的复发率和发生率

Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.

作者信息

Tanaka Koji, Onoe Hajime, Takeshima Keigo, Kono Michiteru, Wakatsuki Yu, Kawamura Akiyuki, Mori Ryusaburo, Nakashizuka Hiroyuki

机构信息

Department of Ophthalmology, Nihon University School of Medicine, Nihon University Hospital, Tokyo, Japan.

Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, 1-6 Kandasurugadai, Chiyoda-ku, Tokyo, 101-8309, Japan.

出版信息

Sci Rep. 2025 May 30;15(1):18975. doi: 10.1038/s41598-025-03782-2.

DOI:10.1038/s41598-025-03782-2
PMID:40447767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12125340/
Abstract

The purpose of this study was to determine the recurrence rate, factors, incidence of polypoidal lesions, and risk factors for developing polypoidal lesions after a reduced dose photodynamic therapy (PDT) for pachychoroid neovasculopathy (PNV) without polypoidal lesions. This study is an observational case-control study. The study included 105 patients (77 men, 28 women; mean age, 61.6 years) with PNV in 105 eyes treated with reduced PDT. Twenty-eight eyes were treated with half-dose PDT and 77 eyes with two-thirds dose PDT, with an average follow-up of 588 days. Logistic regression analysis was used to examine factors of recurrence and polypoidal lesions. Recurrence was observed in six patients (21%) receiving half-dose PDT and 24 patients (31%) receiving two-thirds dose PDT. Polypoidal lesions developed in seven patients (7%). Recurrence factors were duration of follow-up (P < 0.0001), macular neovascularization (MNV) thickness before PDT (P = 0.010), and age (P = 0.002). MNV area before PDT was an independent risk factor for the development of polypoidal lesions (P = 0.001). Long-term follow-up after reduced PDT for PNV is necessary because recurrence factors include follow-up duration, age, and MNV thickness. A risk factor for polypoidal lesions after PNV treatment was the MNV area before PDT.

摘要

本研究的目的是确定在对无息肉样病变的厚脉络膜新生血管病变(PNV)进行减量光动力疗法(PDT)后,其复发率、相关因素、息肉样病变的发生率以及发生息肉样病变的危险因素。本研究是一项观察性病例对照研究。该研究纳入了105例接受减量PDT治疗的PNV患者(77例男性,28例女性;平均年龄61.6岁),共105只眼。28只眼接受半量PDT治疗,77只眼接受三分之二量PDT治疗,平均随访588天。采用逻辑回归分析来研究复发和息肉样病变的相关因素。接受半量PDT治疗的6例患者(21%)和接受三分之二量PDT治疗的24例患者(31%)出现复发。7例患者(7%)出现息肉样病变。复发因素包括随访时间(P<0.0001)、PDT前黄斑新生血管(MNV)厚度(P = 0.010)和年龄(P = 0.002)。PDT前MNV面积是发生息肉样病变的独立危险因素(P = 0.001)。对PNV进行减量PDT后进行长期随访是必要的,因为复发因素包括随访时间、年龄和MNV厚度。PNV治疗后息肉样病变的一个危险因素是PDT前MNV面积。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/3cf770dfae6d/41598_2025_3782_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/25d0f6ab5057/41598_2025_3782_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/7474df5f3401/41598_2025_3782_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/3cf770dfae6d/41598_2025_3782_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/25d0f6ab5057/41598_2025_3782_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/7474df5f3401/41598_2025_3782_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/879a/12125340/3cf770dfae6d/41598_2025_3782_Fig3_HTML.jpg

相似文献

1
Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.半剂量和三分之二剂量光动力疗法治疗厚脉络膜新生血管病变后息肉样病变的复发率和发生率
Sci Rep. 2025 May 30;15(1):18975. doi: 10.1038/s41598-025-03782-2.
2
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.抗血管内皮生长因子用于病理性近视患者脉络膜新生血管化的治疗
Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD011160. doi: 10.1002/14651858.CD011160.pub2.
3
Proton beam irradiation with anti-VEGF therapy for polypoidal choroidal vasculopathy: results of a 24-month, phase II randomized study.质子束照射联合抗血管内皮生长因子治疗息肉样脉络膜血管病变:一项为期24个月的II期随机研究结果
Graefes Arch Clin Exp Ophthalmol. 2025 Mar;263(3):659-668. doi: 10.1007/s00417-024-06681-w. Epub 2024 Nov 9.
4
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight.德国真实环境中使用甲基氨基乙酰丙酸的人工日光光动力疗法:非干预性研究ArtLight的结果
Br J Dermatol. 2025 Feb 18;192(3):510-519. doi: 10.1093/bjd/ljae437.
5
Interventions for central serous chorioretinopathy: a network meta-analysis.中心性浆液性脉络膜视网膜病变的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
6
Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis.光动力疗法联合雷珠单抗与雷珠单抗单药治疗息肉样脉络膜血管病变的系统评价和荟萃分析。
Photodiagnosis Photodyn Ther. 2017 Dec;20:215-220. doi: 10.1016/j.pdpdt.2017.09.008. Epub 2017 Sep 19.
7
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.雷珠单抗和哌加他尼治疗年龄相关性黄斑变性:系统评价与经济学评估
Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. doi: 10.3310/hta12160.
8
One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.无息肉样脉络膜血管病变的厚脉络膜新生血管病变采用半剂量光动力疗法联合玻璃体内注射阿柏西普治疗的一年疗效。
Jpn J Ophthalmol. 2020 Mar;64(2):203-209. doi: 10.1007/s10384-020-00722-7. Epub 2020 Feb 3.
9
Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes.玻璃体内抗血管内皮生长因子药物联合光动力疗法治疗厚脉络膜新生血管病变:长期治疗结局。
Graefes Arch Clin Exp Ophthalmol. 2024 Jun;262(6):1811-1818. doi: 10.1007/s00417-024-06387-z. Epub 2024 Jan 31.
10
Progression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy.特发性脉络膜厚血管病变进展为 1 型动脉瘤样脉络膜新生血管或息肉样脉络膜血管病变。
Ophthalmol Retina. 2022 Sep;6(9):807-813. doi: 10.1016/j.oret.2022.04.004. Epub 2022 Apr 7.

本文引用的文献

1
Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.黄斑新生血管和息肉样脉络膜血管病变:表型变异、发病机制及其在治疗中的意义。
Eye (Lond). 2024 Mar;38(4):659-667. doi: 10.1038/s41433-023-02764-w. Epub 2023 Oct 6.
2
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy.半剂量光动力疗法联合阿柏西普治疗厚脉络膜新生血管病变的疗效预测因素。
Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2235-2243. doi: 10.1007/s00417-023-06030-3. Epub 2023 Mar 8.
3
Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration.
用于预测渗出性新生血管性年龄相关性黄斑变性转化的光学相干断层扫描生物标志物
Am J Ophthalmol. 2023 Mar;247:137-144. doi: 10.1016/j.ajo.2022.09.018. Epub 2022 Oct 11.
4
Progression of Polypoidal Lesions Associated with Exudative Recurrence in Polypoidal Choroidal Vasculopathy.息肉样病变与息肉样脉络膜血管病变渗出性复发相关的进展。
Ophthalmology. 2023 Feb;130(2):167-178. doi: 10.1016/j.ophtha.2022.09.013. Epub 2022 Sep 22.
5
Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.治疗初发新生血管性年龄相关性黄斑变性的 brolucizumab 短期疗效:一项日本多中心研究。
Jpn J Ophthalmol. 2022 Jul;66(4):379-385. doi: 10.1007/s10384-022-00922-3. Epub 2022 May 21.
6
Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy.光动力疗法治疗息肉样脉络膜血管病变 5 年后的黄斑萎缩。
Eye (Lond). 2023 Apr;37(6):1067-1072. doi: 10.1038/s41433-022-02067-6. Epub 2022 Apr 14.
7
Progression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy.特发性脉络膜厚血管病变进展为 1 型动脉瘤样脉络膜新生血管或息肉样脉络膜血管病变。
Ophthalmol Retina. 2022 Sep;6(9):807-813. doi: 10.1016/j.oret.2022.04.004. Epub 2022 Apr 7.
8
Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy.三分之二剂量光动力疗法治疗厚脉络膜新生血管病变
J Clin Med. 2021 May 17;10(10):2168. doi: 10.3390/jcm10102168.
9
One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy.脉络膜厚血管病变行抗血管内皮生长因子和半剂量光动力疗法治疗一年的对比观察。
Eye (Lond). 2021 Dec;35(12):3367-3375. doi: 10.1038/s41433-021-01418-z. Epub 2021 Feb 9.
10
One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy.玻璃体内抗血管内皮生长因子与光动力疗法联合治疗厚脉络膜新生血管病变患者的一年疗效
Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1279-1285. doi: 10.1007/s00417-020-04661-4. Epub 2020 Mar 31.